Skip NavigationSkip to Content

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

  1. Author:
    Luckay, A.
    Sidhu, M. K.
    Kjeken, R.
    Megati, S.
    Chong, S. Y.
    Roopch, V.
    Garcia-H, D.
    Abdullah, R.
    Braun, R.
    Montefiori, D. C.
    Rosati, M.
    Felber, B. K.
    Pavlakis, G. N.
    Mathiesen, I.
    Israel, Z. R.
    Eldridge, J. H.
    Egan, M. A.
  2. Author Address

    Wyeth Vaccines Res, Vaccine Discovery, Pearl River, NY 10965 USA. Inovio AS, N-0373 Oslo, Norway. Duke Univ, Ctr Med, Dept Surg, Durham, NC 27710 USA. Natl Canc Inst Frederick, Human Retrovirus Sect, Ft Detrick, MD 21702 USA. Natl Canc Inst Frederick, Human Retrovirus Pathogenesis Sect, Ft Detrick, MD 21702 USA.;Egan, MA, Wyeth Vaccines Res, Vaccine Discovery, 401 N Middletown Rd, Pearl River, NY 10965 USA.;eganm@wyeth.com
    1. Year: 2007
    2. Date: May
  1. Journal: Journal of Virology
    1. 81
    2. 10
    3. Pages: 5257-5269
  2. Type of Article: Article
  3. ISSN: 0022-538X
  1. Abstract:

    Since human immunodeficiency virus (HIV)-specific cell-mediated immune (CMI) responses are critical in the early control and resolution of HIV infection and correlate with postchallenge outcomes in rhesus macaque challenge experiments, we sought to identify a plasmid DNA (pDNA) vaccine design capable of eliciting robust and balanced CMI responses to multiple HIV type 1 (HIV-1)-derived antigens for further development. Previously, a number of two-, three-, and four-vector pDNA vaccine designs were identified as capable of eliciting HIV-1 antigen-specific CMI responses in mice (M. A. Egan et al., Vaccine 24:4510-4523, 2006). We then sought to further characterize the relative immunogenicities of these two-, three-, and four-vector pDNA vaccine designs in nonhuman primates and to determine the extent to which in vivo electroporation (EP) could improve the resulting immune responses. The results indicated that a two-vector pDNA vaccine design elicited the most robust and balanced CMI response. In addition, vaccination in combination with in vivo EP led to a more rapid onset and enhanced vaccine-specific immune responses. In macaques immunized in combination with in vivo EP, we observed a 10- to 40-fold increase in HIV-specific enzyme-linked immunospot assay responses compared to those for macaques receiving a 5-fold higher dose of vaccine without in vivo EP. This increase in CMI responses translates to an apparent 50- to 200-fold increase in pDNA vaccine potency. Importantly, in vivo EP enhanced the immune response against the less immunogenic antigens, resulting in a more balanced immune response. In addition, in vivo EP resulted in an approximate 2.5-log(10) increase in antibody responses. The results further indicated that in vivo EP was associated with a significant reduction in pDNA persistence and did not result in an increase in pDNA associated with high-molecular-weight DNA relative to macaques receiving the pDNA without EP. Collectively, these results have important implications for the design and development of an efficacious vaccine for the prevention of HIV-1 infection.

    See More

External Sources

  1. DOI: 10.1128/jvi.00055-07
  2. WOS: 000246464200034

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel